Low-molecular-weight heparins: Are they interchangeable?

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 148-157

  Van Der Heijden, Jeroen F ^a,b   Prins, Martin H ^a   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Initial treatment; Low molecular weight heparin; Meta analysis; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0034461185     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054183     Document Type: Conference Paper

References (46)

1. Low-molecular-weight heparins
2. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
3. Low-molecular-weight heparins in venous and arterial thrombotic disease
4. Statistical aspects of the analysis of data from retrospective studies of disease
5. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews
6. For the initial treatment of venous thromboembolism: Are all low-molecular-weight heparin compounds the same?
7. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis
8. Subcutaneous KABI 2165 in the treatment of deep vein thrombosis of the leg
9. Fixed dose LMW heparin (CY216) as compared with adjusted dose intravenous heparin in the initial treatment of symptomatic proximal venous thrombosis
10. A randomized double-blind trial of low-molecular-weight heparin in the initial treatment of proximal venous thrombosis
11. A multicenter clinical trial comparing once-daily and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis
12. Efficacy and safety of a low molecular weight heparin (LMW-heparin Sandoz) in patients with deep vein thrombosis
13. Efficacy and safety of a low molecular weight heparin (enoxaparin) and unfractionated heparin in proximal deep vein thrombosis
14. Fragmin once daily versus continuous infusion heparin in the treatment of DVT: A European multicentre trial
15. Subcutanous administration of a low molecular weight heparin (CY222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis
16. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT
17. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)
18. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
19. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
20. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis
21. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
22. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
23. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
24. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
25. Traitment des thromboses veineuses profondes constituées: Etude comperative d'un fragment d'héparine de bas poids moléculaire (Fragmine) administrée par voie souscutanée et de l'héparine standard administrée par voie intraveineuse continue
26. Deep vein thrombosis of the legs: New therapy by means of low molecular weight heparins
27. Low molecular weight heparin in the short and long term treatment of deep vein thrombosis in diabetic subjects
28. Antithrombotic therapy in phlebopathies of lower limbs: A controlled study of low molecular weight heparin versus heparin calcium
29. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis
30. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism
31. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
32. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
33. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
34. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
35. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
36. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
37. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
38. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
39. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
40. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
41. Treatment of acute DVT with the low molecular weight heparin (LMWH) Reviparin: Results of the Cortes-study
42. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
43. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
44. Un nouveau traitement des thromboses veineuses profondes: Les fractions d'héparine de bas poids moléculaire. Etude randomisée
45. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
46. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis